Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

News Daily News

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

Michael O'Riordan

July 31, 2025

AI Has Great Potential in CV Pharmacotherapy, but Much Work Lies Ahead: Review

News Daily News

AI Has Great Potential in CV Pharmacotherapy, but Much Work Lies Ahead: Review

July 24, 2025

Prepregnancy CV Health Portends Midlife Risks: CARDIA Analysis

News Daily News

Prepregnancy CV Health Portends Midlife Risks: CARDIA Analysis

June 27, 2025

Weight-Loss Medications Should Be Part of Cardiology’s Arsenal: ACC

News Daily News

Weight-Loss Medications Should Be Part of Cardiology’s Arsenal: ACC

Michael O'Riordan

June 25, 2025

Amylin Analogue Boosts Weight Loss When Added to GLP-1

News Daily News

Amylin Analogue Boosts Weight Loss When Added to GLP-1

June 24, 2025

App-Based Support Aids Weight Loss With Semaglutide, Studies Show

News Conference News European Congress on Obesity 2025

App-Based Support Aids Weight Loss With Semaglutide, Studies Show

Michael O'Riordan

May 13, 2025

April 2025 Dispatch for the CV Team

News Opinion CV Team Dispatch

April 2025 Dispatch for the CV Team

April 18, 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients

News Daily News ACC 2025

STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients

March 29, 2025

March 2025 Dispatch for the CV Team

News Opinion CV Team Dispatch

March 2025 Dispatch for the CV Team

March 21, 2025

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

News Daily News

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Michael O'Riordan

February 20, 2025

January 2025 Dispatch for the CV Team

News Opinion CV Team Dispatch

January 2025 Dispatch for the CV Team

January 24, 2025

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

News Daily News

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Michael O'Riordan

January 22, 2025

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.